Kritzer G, Warr T A, Strong M L, Froelicher V F
Clin Pharm. 1983 May-Jun;2(3):236-42.
The efficacy and safety of atenolol was evaluated in 16 patients with exertional angina pectoris in a single-blind, once daily, increasing dose study. All patients had coronary artery disease documented by previous myocardial infarction, coronary angiography, or an abnormal exercise ECG. After a four-week placebo period, patients received 25, 50, and 100 mg of atenolol once daily during three two-week periods. This was followed by a three-week treatment period with 200 mg of atenolol once daily. The study was concluded with a two to four week posttreatment period. Antianginal efficacy was assessed by monitoring changes in treadmill exercise performance in each patient 3 and 24 hours after the administration of atenolol. The endpoint of the treadmill exercise was mild but definite chest pain. At 3 and 24 hours after all dosages, atenolol significantly prolonged the duration of exercise and increased the work performed. The pulse rate and double product at the endpoint of exercise were lower with all atenolol doses. Overall, at 24 hours after the administration of atenolol, exercise tolerance was progressively increased as the dose increased. The mean duration of exercise and work performed increased 28.5 and 35.4%, respectively, on the 25-mg dose; 36.9 and 45.5%, respectively, on the 50-mg dose; 45.1 and 59.5%, respectively, on the 100-mg dose; and 65.4 and 84.8%, respectively, on the 200-mg dose. Patient acceptance and compliance were good. Single daily doses of atenolol constitute effective therapy for exercise-induced angina.
在一项单盲、每日一次递增剂量研究中，对16例劳力性心绞痛患者评估了阿替洛尔的疗效和安全性。所有患者均有既往心肌梗死、冠状动脉造影或运动心电图异常所证实的冠状动脉疾病。经过4周的安慰剂期后，患者在三个为期两周的阶段中每日一次接受25、50和100毫克阿替洛尔治疗。随后是为期三周的阶段，每日一次服用200毫克阿替洛尔。研究以两到四周的治疗后期结束。通过监测每位患者在服用阿替洛尔后3小时和24小时的跑步机运动表现变化来评估抗心绞痛疗效。跑步机运动的终点是轻度但明确的胸痛。在所有剂量给药后3小时和24小时，阿替洛尔均显著延长了运动持续时间并增加了做功量。所有阿替洛尔剂量下运动终点时的脉搏率和双乘积均较低。总体而言，在服用阿替洛尔后24小时，运动耐量随剂量增加而逐渐提高。在25毫克剂量时，运动平均持续时间和做功量分别增加了28.5%和35.4%；在50毫克剂量时，分别增加了36.9%和45.5%；在100毫克剂量时，分别增加了45.1%和59.5%；在200毫克剂量时，分别增加了65.4%和84.8%。患者的接受度和依从性良好。每日单次剂量的阿替洛尔是治疗运动诱发型心绞痛的有效疗法。
